sulfaquinoxalina® sulfamont solución oral
biomont - sulfaquinoxalina; vitamina k3 (menadiona); - solución oral - sulfaquinoxalina 3.4 g; vitamina k3 (menadiona) 215 mg; excipientes c.s.p - antibacterianos (antibioticos); sulfonamidas – trimetoprim; antiparasitarios internos; antiprotozoarios; coccidia; vitaminas; asociadas con medicamentos - aves de corral; conejos - coccidiosis; enteritis bacteriana
sulfametazina al 30 % retardada rio de janeiro
allignani hnos. - sulfametazina sódica - solución inyectable - sulfametazina sódica 30 g. - coccidiosis, infecciones del tracto respiratorio superior e inferior, mastitis, toxoplasmosis, pietin, actinomicosis, actinobacilosis, poliartritis, colibacilosis, salmonellosis y cualquier infección causada por microorganismos sensibles a la sulfametazina. - bovinos; caninos; caprinos; equinos; ovinos; porcinos
kosswell profesional koxidil regenerate treatment,tratamiento activo anticaida
global cosmetic chile s.p.a. - sin formulas
noxafil
merck sharp and dohme b.v - posaconazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimicóticos para uso sistémico - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 y 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 y 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refractariedad se define como la progresión de la infección o el fracaso a mejorar después de un mínimo de 7 días antes de la dosis terapéutica de un eficaz tratamiento antifúngico. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 y 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 y 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 y 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refractariedad se define como la progresión de la infección o el fracaso a mejorar después de un mínimo de 7 días antes de la dosis terapéutica de un eficaz tratamiento antifúngico. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 y 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 y 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refractariedad se define como la progresión de la infección o el fracaso a mejorar después de un mínimo de 7 días antes de la dosis terapéutica de un eficaz tratamiento antifúngico. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- la aspergilosis invasiva en pacientes con enfermedad refractaria a la anfotericina b, itraconazol o en pacientes que son intolerantes a estos medicamentos;- fusariosis en pacientes con enfermedad refractaria a la anfotericina b, o en pacientes que son intolerantes a la de la anfotericina b;- chromoblastomycosis y mycetoma en pacientes con enfermedad refractaria a itraconazol o en pacientes que son intolerantes a la de itraconazol;- la coccidioidomicosis en pacientes con enfermedad refractaria a la anfotericina b, itraconazol o fluconazol o en pacientes que son intolerantes a estos medicamentos;- candidiasis orofaríngea: como terapia de primera línea en los pacientes que tienen enfermedad grave o que están inmunocomprometidos, en los que la respuesta a la terapia tópica se espera que para ser pobre. la refractariedad se define como la progresión de la infección o el fracaso a mejorar después de un mínimo de 7 días antes de la dosis terapéutica de un eficaz tratamiento antifúngico. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.
amproline 400 mg/ml solucion para administracion en agua de bebida para pollos y pavos # amproline 400 mg/ml solución para administración en agua de bebida para pollos y pavos
huvepharma s.a. - amprolio hidrocloruro - soluciÓn para administraciÓn en agua de bebida - amprolio hidrocloruro 452,4 - amprolio - pavos; gallinas ponedoras; pollos de engorde; pollitas; gallinas reproductoras
cocciklass 50 mg/ml suspension oral
mevet s.a.u. - toltrazurilo - suspensiÓn oral - toltrazurilo 50 - toltrazurilo - lechones
tolvet 50 mg/ml suspension oral para porcino
vetpharma animal health s.l. - toltrazurilo - suspensiÓn oral - toltrazurilo 50 - toltrazurilo - lechones
zuritol 50 mg/ml suspension oral para porcino
laboratorios calier s.a. - toltrazurilo - suspensiÓn oral - toltrazurilo 50 - toltrazurilo - lechones
zorabel 50 mg/ml suspension oral para porcino # tolcox 50 mg/ml suspension oral para porcino
vetpharma animal health s.l. - toltrazurilo - suspensiÓn oral - toltrazurilo 50 - toltrazurilo - lechones
tolcocx solución oral
biomont, - toltrazuril; vitamina k3 (menadiona) - solución oral - toltrazuril 5 g;vitamina k3 (menadiona) 500 mg;excipientes c.s.p , toltrazuril 5 g; vitamina k3 (menadiona) 500 mg; excipientes c.s.p - agentes de uso múltiple: antihemorrágicos. antiparasitarios internos: antiprotozoarios, coccidia. - aves de corral, porcinos, vacunos - tolcocx, es un producto formulado a base de toltrazuril y vitamina k3 , indicado para la prevención y tratamiento de infecciones causadas por coccidias (eimeria spp., isospora suis). la vitamina k3 asociado al toltrazuril, promueve la coagulación sanguínea a través de la regulación y el mantenimiento de la formación de protrombina permitiendo así una pronta recuperación de las lesiones intestinales asociadas a la coccidiosis.